Fernando de la Hoz1, Ligia Perez, Marlen de Neira, Andrew J Hall. 1. Universidad Nacional de Colombia, Ciudad Universitaria, Cra 30 Cll 45, Edificio 471, Facultad de Medicina, Oficina 150, Bogotá, Colombia. fpdelahozr@unal.edu.co
Abstract
OBJECTIVE: To evaluate the effectiveness of a recombinant hepatitis B vaccine used in endemic areas of Colombia, as well as risk factors associated with hepatitis B virus (HBV) infection and carriage after vaccine introduction. METHODS: A cross-sectional study was carried out in urban and rural areas of the Colombian Amazon, a highly endemic area for hepatitis B infection. Children under 12 years of age and their mothers were selected for the study using one-stage cluster sampling (N=2145) and were examined for HBV serological markers and antibodies against surface antigen (anti-HBs). RESULTS: There has been a reduction of 60-75% in the prevalence of HBV infection and hepatitis B surface antigen (HBsAg) carriage since HBV vaccination was introduced. Receiving the first dose of HBV vaccine at more than two months after birth was one of the factors associated with HBV carrier status. Maternal HBV infection was also associated with infection in the child. CONCLUSIONS: The recombinant Cuban hepatitis B vaccine has contributed to the reduction of the infection in this highly endemic area, though further efforts are required to improve timely vaccination for children at high risk.
OBJECTIVE: To evaluate the effectiveness of a recombinant hepatitis B vaccine used in endemic areas of Colombia, as well as risk factors associated with hepatitis B virus (HBV) infection and carriage after vaccine introduction. METHODS: A cross-sectional study was carried out in urban and rural areas of the Colombian Amazon, a highly endemic area for hepatitis B infection. Children under 12 years of age and their mothers were selected for the study using one-stage cluster sampling (N=2145) and were examined for HBV serological markers and antibodies against surface antigen (anti-HBs). RESULTS: There has been a reduction of 60-75% in the prevalence of HBV infection and hepatitis B surface antigen (HBsAg) carriage since HBV vaccination was introduced. Receiving the first dose of HBV vaccine at more than two months after birth was one of the factors associated with HBV carrier status. Maternal HBV infection was also associated with infection in the child. CONCLUSIONS: The recombinant Cuban hepatitis B vaccine has contributed to the reduction of the infection in this highly endemic area, though further efforts are required to improve timely vaccination for children at high risk.
Authors: Lana Childs; Paul Adrien; Anna A Minta; Jeannot François; Nadia Phaïmyr Jn Charles; Valery Blot; Gloria Rey-Benito; Jodi L Vanden Eng; Rania A Tohme Journal: Am J Trop Med Hyg Date: 2019-07 Impact factor: 2.345
Authors: Márcia da Costa Castilho; Cintia Mara Costa de Oliveira; João Bosco de Lima Gimaque; Jorge Di Tommaso Leão; Wornei Silva Miranda Braga Journal: Am J Trop Med Hyg Date: 2012-08-20 Impact factor: 2.345
Authors: Maria-Cristina Navas; Iris Suarez; Andrea Carreño; Diego Uribe; Wilson Alfredo Rios; Fabian Cortes-Mancera; Ghyslaine Martel; Beatriz Vieco; Diana Lozano; Carlos Jimenez; Doriane Gouas; German Osorio; Sergio Hoyos; Juan Carlos Restrepo; Gonzalo Correa; Sergio Jaramillo; Rocio Lopez; Luis Eduardo Bravo; Maria Patricia Arbelaez; Jean-Yves Scoazec; Behnoush Abedi-Ardekani; Regina M Santella; Isabelle Chemin; Pierre Hainaut Journal: Hepat Res Treat Date: 2011-10-31
Authors: Haimanti Bhattacharya; Debdutta Bhattacharya; S R Ghosal; Subarna Roy; A P Sugunan Journal: Indian J Med Res Date: 2015-05 Impact factor: 2.375